Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Taiichi Kyo, M.D., Kouhei Kyo, MD, Ryouta Imanaka, M.D., Mitsuhiro Itagaki, MD, Tetsuro Ochi, Takeshi Okatani, M.D., Koji Iwato, MD, Yuta Katayama, MD, PhD, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 1571.

https://doi.org/10.1182/blood.V122.21.1571.1571

Published: 2013

Journal Articles

Long-Term Outcome of All-Trans-Retinoic-Acid(ATRA)+Intensive Chemotherapy in Acute Promyelocytic Leukemia(APL),

Taiichi Kyo, M.D., Takeshi Okatani, M.D., Kouhei Kyo, M.D., Mitsuhiro Itagaki, M.D., Ryouta Imanaka, M.D., Koji Iwato, M.D., Hidkeki Asaoku, M.D., Yuuta Katayama, M.D.

Blood (2011) 118 (21): 3604.

https://doi.org/10.1182/blood.V118.21.3604.3604

Published: 2011

Journal Articles

Early Diagnostic Procedure and Treatment for Invasive Fungal Infection Centered on Invasive Aspergillosis in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

Kouhei Kyo, M.D., Takeshi Okatani, M.D., Ryota Imanaka, M.D., Mitsuhiro Itagaki, M.D., Yuuta Katayama, M.D., Taiichi Kyo, M.D.

Blood (2011) 118 (21): 1544.

https://doi.org/10.1182/blood.V118.21.1544.1544

Published: 2011

Journal Articles

Results of Treatment with Tyrosine Kinase Inhibitors(TKIs) in Combination with Intensive Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia(Ph+ALL)

Taiichi Kyo, M.D., Takeshi Okatani, M.D., Kouhei Kyo, Ryouta Imanaka, M.D., Mitsuhiro Itagaki, M.D., Yuuta Katayama, MD, Koji Iwato, M.D., Hideki Asaoku, MD

Blood (2011) 118 (21): 1503.

https://doi.org/10.1182/blood.V118.21.1503.1503

Published: 2011

Journal Articles

t(8;21)-Positive AML with Mutant Kit Is a Novel Therapeutic Target of Imatinib Mesylate.

Hiroya Asou, M.D., Taiichi Kyo, M.D., Toshiya Inaba, M.D.

Blood (2004) 104 (11): 1164.

https://doi.org/10.1182/blood.V104.11.1164.1164

Published: 2004

NARROW

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Long-Term Outcome of All-Trans-Retinoic-Acid(ATRA)+Intensive Chemotherapy in Acute Promyelocytic Leukemia(APL),

Early Diagnostic Procedure and Treatment for Invasive Fungal Infection Centered on Invasive Aspergillosis in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

Results of Treatment with Tyrosine Kinase Inhibitors(TKIs) in Combination with Intensive Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia(Ph+ALL)

t(8;21)-Positive AML with Mutant Kit Is a Novel Therapeutic Target of Imatinib Mesylate.

Email alerts

ASH Publications

American Society of Hematology

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Long-Term Outcome of All-Trans-Retinoic-Acid(ATRA)+Intensive Chemotherapy in Acute Promyelocytic Leukemia(APL),

Early Diagnostic Procedure and Treatment for Invasive Fungal Infection Centered on Invasive Aspergillosis in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

Results of Treatment with Tyrosine Kinase Inhibitors(TKIs) in Combination with Intensive Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia(Ph+ALL)

t(8;21)-Positive AML with Mutant Kit Is a Novel Therapeutic Target of Imatinib Mesylate.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only